+

WO2002055532A3 - Molecules d'hormone de croissance ameliorees - Google Patents

Molecules d'hormone de croissance ameliorees Download PDF

Info

Publication number
WO2002055532A3
WO2002055532A3 PCT/DK2002/000017 DK0200017W WO02055532A3 WO 2002055532 A3 WO2002055532 A3 WO 2002055532A3 DK 0200017 W DK0200017 W DK 0200017W WO 02055532 A3 WO02055532 A3 WO 02055532A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth hormone
macromolecular compounds
molecules conjugated
polypeptide
hormone molecules
Prior art date
Application number
PCT/DK2002/000017
Other languages
English (en)
Other versions
WO2002055532A2 (fr
Inventor
Kim Vilbour Andersen
Jørn DRUSTRUP
Jesper Christiansen
Original Assignee
Maxygen Aps
Maxygen Holdings Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Aps, Maxygen Holdings Ltd. filed Critical Maxygen Aps
Priority to AU2002219021A priority Critical patent/AU2002219021A1/en
Priority to EP02729417A priority patent/EP1352062A2/fr
Priority to JP2002556600A priority patent/JP2004524020A/ja
Priority to US10/250,800 priority patent/US20060183197A1/en
Publication of WO2002055532A2 publication Critical patent/WO2002055532A2/fr
Publication of WO2002055532A3 publication Critical patent/WO2002055532A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

L'invention concerne des conjugués possédant une activité d'hormone de croissance (GH), et contenant au moins une première fraction non polypeptidique liée de manière covalente à un polypeptide de GH dont la séquence d'acides aminés diffère de celle d'une hormone de croissance de type sauvage par au moins un résidu d'acide aminé introduit et au moins un résidu d'acide aminé enlevé comprenant un groupe de liaison se fixant à ladite première fraction non polypeptidique. Cette première fraction non polypeptidique est par exemple une molécule polymère ou une fraction sucre. Les conjugué sont particulièrement utiles en thérapie.
PCT/DK2002/000017 2001-01-11 2002-01-10 Molecules d'hormone de croissance ameliorees WO2002055532A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002219021A AU2002219021A1 (en) 2001-01-11 2002-01-10 Variant growth hormone molecules conjugated with macromolecular compounds
EP02729417A EP1352062A2 (fr) 2001-01-11 2002-01-10 Molecules d'hormone de croissance ameliorees
JP2002556600A JP2004524020A (ja) 2001-01-11 2002-01-10 改良された成長ホルモン分子
US10/250,800 US20060183197A1 (en) 2001-01-11 2002-01-10 Variant growth hormone molecules conjugated with macromolecules compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26141101P 2001-01-11 2001-01-11
US60/261,411 2001-01-11
DKPA200100042 2001-01-11
DKPA200100042 2001-01-11

Publications (2)

Publication Number Publication Date
WO2002055532A2 WO2002055532A2 (fr) 2002-07-18
WO2002055532A3 true WO2002055532A3 (fr) 2002-09-19

Family

ID=26068940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000017 WO2002055532A2 (fr) 2001-01-11 2002-01-10 Molecules d'hormone de croissance ameliorees

Country Status (4)

Country Link
EP (1) EP1352062A2 (fr)
JP (1) JP2004524020A (fr)
AU (1) AU2002219021A1 (fr)
WO (1) WO2002055532A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
EP1453859A2 (fr) * 2001-11-20 2004-09-08 Pharmacia Corporation Conjugues de l'hormone de croissance humaine chimiquement modifiee
WO2004020468A2 (fr) * 2002-08-28 2004-03-11 Maxygen Aps Molecules d'interferon de type $g(b) pour le traitement du cancer
WO2005034988A1 (fr) * 2003-10-10 2005-04-21 Novo Nordisk A/S Molecules a action prolongee contenues dans des formulations a liberation prolongee
MXPA06008209A (es) * 2004-01-21 2006-08-31 Novo Nordisk As Conjugacion de peptidos mediada por transglutaminasa.
EP1833993A4 (fr) * 2004-12-22 2009-07-22 Ambrx Inc Formulations d'hormone de croissance humaine comportant un acide aminé codé de manière non naturelle
EP1893239A2 (fr) * 2005-06-15 2008-03-05 Novo Nordisk Health Care AG Conjugaison mediee par la transglutaminase d'une hormone de croissance
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
CA2655188A1 (fr) * 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag Nouveaux conjugues de proteines et leurs procedes de preparation
EP2323694A1 (fr) 2008-08-06 2011-05-25 Novo Nordisk Health Care AG Protéines conjuguées à efficacité in vivo prolongée
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
CN102612376A (zh) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
RU2012129674A (ru) 2009-12-15 2014-01-27 Аспендис Фарма Ас Композиция гормона роста
SI2525834T1 (sl) * 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Rastni hormoni s podaljšano in vivo učinkovitostjo
EP2595661A1 (fr) 2010-07-22 2013-05-29 Novo Nordisk Health Care AG Conjugués d'hormone de croissance
EP2970506A1 (fr) 2013-03-11 2016-01-20 Novo Nordisk Health Care AG Composés d'hormone de croissance
WO2014166836A1 (fr) 2013-04-05 2014-10-16 Novo Nordisk A/S Formulation de composés d'hormone de croissance
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
CN114835793A (zh) * 2015-11-16 2022-08-02 Ubi蛋白公司 用于延长蛋白质半衰期的方法
WO2018185131A2 (fr) 2017-04-05 2018-10-11 Novo Nordisk A/S Conjugués insuline-fc à extension oligomère

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458064A2 (fr) * 1990-05-04 1991-11-27 American Cyanamid Company Stabilisation de la somatotropine et autres protéines à travers une modification des résidus de cystéine
WO1995011987A1 (fr) * 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Proteines chimeres contenant des variantes de la protease nexine-1
WO1997011178A1 (fr) * 1995-09-21 1997-03-27 Genentech, Inc. Variants de l'hormone de croissance humaine
WO1999003887A1 (fr) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derives d'hormone de croissance et proteines associees
WO2000042175A1 (fr) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Techniques permettant de produire des proteines contenant des residus cysteine libres

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458064A2 (fr) * 1990-05-04 1991-11-27 American Cyanamid Company Stabilisation de la somatotropine et autres protéines à travers une modification des résidus de cystéine
WO1995011987A1 (fr) * 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Proteines chimeres contenant des variantes de la protease nexine-1
WO1997011178A1 (fr) * 1995-09-21 1997-03-27 Genentech, Inc. Variants de l'hormone de croissance humaine
WO1999003887A1 (fr) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derives d'hormone de croissance et proteines associees
WO2000042175A1 (fr) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Techniques permettant de produire des proteines contenant des residus cysteine libres

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
B C CUNNINGHAM & J A WELLS: "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis", SCIENCE., vol. 244, 2 June 1989 (1989-06-02), AAAS. LANCASTER, PA., US, pages 1081 - 1085, XP000025308, ISSN: 0036-8075 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation

Also Published As

Publication number Publication date
WO2002055532A2 (fr) 2002-07-18
EP1352062A2 (fr) 2003-10-15
AU2002219021A1 (en) 2002-07-24
JP2004524020A (ja) 2004-08-12

Similar Documents

Publication Publication Date Title
WO2002055532A3 (fr) Molecules d'hormone de croissance ameliorees
DE69813291T2 (de) Herstellung stellen-spezifischer polyethylenglycol-grf konjugate
WO2002074806A3 (fr) Nouvelles molecules de type interferon beta
WO2001051510A3 (fr) Produits conjugues g-csf
WO2001036001A3 (fr) Conjugues d'interferon gamma
WO2001015736A3 (fr) Nouvelles molecules analogues a l'interferon beta
EP1221975B1 (fr) Neuropeptides stabilises par des polymeres
WO2001058493A8 (fr) Conjugates of follicle stimulating hormones
WO2005056760A3 (fr) Hormone stimulant le follicule humain glycopegyle
US20090221471A1 (en) Prodrugs of vancomycin with hydrolysis resistant polymer linkages
IL206445A0 (en) Peptide conjugate of exendin-4(1-39)variant in combination with an antidiabetic agent for use in the treatment of type 2 diabetes mellitus
WO2003055916A3 (fr) Fragments et conjugues de l'adiponectine
WO1999048536A3 (fr) Apport local d'agents therapeutiques a action prolongee
EP1137442B1 (fr) Conjugues biologiquement actifs contenant un groupe rapporteur detectable et methode d'identification dudit derive
CA2498062A1 (fr) Conjugues de proteine de liaison du facteur de croissance insulinomimetique 4 et de poly(ethylene glycol)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002729417

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002556600

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002729417

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2006183197

Country of ref document: US

Ref document number: 10250800

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002729417

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10250800

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载